Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 2/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19260832 | 0.85 | CA12 (0.36) | CCR4GPR119PIK3CDPIP5K1CPIK3CB | |
| SCHEMBL16430696 | 0.78 | PSIP1 (0.31) | EDNRA | |
| SCHEMBL426787 | 0.77 | EDNRA (0.35) | CCR4EDNRA | |
| SCHEMBL2636770 | 0.77 | POLB (0.33) | GPR119 | |
| SCHEMBL3599216 | 0.74 | GPR119 (0.31) | GPR119PIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL13484393 | 0.74 | PTGS2 (0.34) | GPR119PIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL7045227 | 0.73 | ALOX5AP (0.40) | GPR119PIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL3599220 | 0.73 | ENPP2 (0.33) | GPR119PIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL422105 | 0.73 | SIRT6 (0.38) | CCR4EDNRAGPR119PIK3CDPIP5K1C | |
| SCHEMBL31035841 | 0.73 | ALOX5AP (0.40) | GPR119PIK3CDPIP5K1CPIK3CBPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION | 2025-03-06 | — | — | US | disclosed |
| WO-2024249252-A1 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024040235-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-2828243-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3027625-B1 | SPIRO-FUSED DERIVATIVES OF PIPERIDINE USEFUL FOR THE TREATMENT OF INTER ALIA HYPERTENSION AND ACUTE OR CHRONIC HEART FAILURE | MERCK SHARP & DOHME (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9751881-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-09-05 | — | — | US | disclosed |
| CN-104220426-B | Estrogen receptor modulators and uses thereof | 塞拉根制药公司 | 2017-03-01 | — | — | CN | disclosed |
| US-9499538-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2239253-B1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-8415359-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2012151158-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-26 | — | — | US | disclosed |
| US-8017610-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| CN-102015637-A | Novel phenylpyrrole derivatives | DAIICHI SANKYO CO LTD | 2011-04-13 | — | — | CN | disclosed |
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2239253-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | CCR4 3702/4885EDNRA 1477/4885GPR119 5/4885 |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | CCR4 3702/4885EDNRA 1477/4885GPR119 5/4885 |
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | CDK2, CDK20, CDK2AP1 | CCR4 4236/4885EDNRA 4580/4885GPR119 4148/4885 |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | CYP3A7, CYP11B2, CYP11B1 | CCR4 825/4885EDNRA 2404/4885GPR119 149/4885 |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | CCR4 1254/4885EDNRA 576/4885GPR119 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.